Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 16, 2009, Pages 6073-6084

  Aubry, Carine ^a   Wilson, A James ^a   Emmerson, Daniel ^a   Murphy, Emma ^a   Chan, Yu Yam ^a   Dickens, Michael P ^a   García, Marcos D ^a   Jenkins, Paul R ^a   Mahale, Sachin ^b   Chaudhuri, Bhabatosh ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Anti cancer; CDK4 inhibitors; Fascaplysin; Indoles

Indexed keywords

1,2 BIS(INDOL 1 YL)ETHANE; 5 CHLORO 3 [2 (5 CHLORO 3A,7A DIHYDROINDOL 1 YL)ETHYL] 1H INDOLE; ALKANE DERIVATIVE; CYCLIN A; CYCLIN D1; CYCLIN D1 INHIBITOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; FASCAPLYSIN; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING;

BINDING SITES; COMPUTER SIMULATION; CYCLIN A; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; DRUG DESIGN; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS;

EID: 68149141339     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.06.070     Document Type: Article

References (43)

1. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts K.; Walter, P. In Molecular Cell Biology, 4th ed.; Garland, New York, 2002, Chapter 17.
2. Huwe A., Mazitschek R., and Giannis A. Angew. Chem., Int. Ed. 42 (2003) 2122
3. DePinto W., et al. Mol. Cancer Ther. 5 (2006) 2644
4. Vander Wel S.N., et al. J. Med. Chem. 48 (2005) 2371
5. Honma T., et al. J. Med. Chem. 44 (2001) 4628
6. Toogood P.L., et al. J. Med. Chem. 48 (2005) 2388
7. Malumbres M., Pevarello P., Barbacid M., and Bischoff J.R. Trends Pharmacol. Sci. 29 (2007) 16
8. Malumbres M., and Barbacid M. Cancer Cell 9 (2006) 2
9. Yu Q., Sicinska E., Ahnstrom M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., Stal O., and Sicinski P. Cancer Cell 9 (2006) 23
10. Landis M.W., Pawlyk B.S., Li T., Sicinski P., and Hinds P.W. Cancer Cell 9 (2006) 13
11. Tetsu O., and McCormick E. Cancer Cell 3 (2003) 233
12. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., and Meijer L. Nat. Cell Biol. 1 (1999) 60
13. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., et al. Nat. Cell Biol. 1 (1999) 60
14. Marko D., Schätzle S., Friedel A., Genzlinger A., Zankl H., and Eisenbrand G. Br. J. Cancer 84 (2001) 283
15. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., et al. J. Biol. Chem. 276 (2001) 251
16. Hong C., Kim H.-A., Firestone G.L., and Bjeldanes L.F. Carcinogenesis 23 (2002) 1297
17. Omura S., Iwai Y., Hirano A., Nakagawa A., Awaya J., Tsuchya H., Takahashi Y., and Masuma R. J. Antibiot. 30 (1977) 275
18. Rialet V., and Meijer L. Anticancer Res. 11 (1991) 1581
19. Roll D.M., Ireland C.M., Lu H.S.M., and Clardy J. J. Org. Chem. 53 (1988) 3276
20. Fischer P.M., Endicott J., and Meijer L. Prog. Cell Cycle Res. 5 (2003) 235
21. Soni R., Muller L., Ferut P., Schoepfer J., Stephan C., Zumstein-Mecker S., Fretz H., and Chaudhuri B. Biochem. Biophys. Res. 275 (2000) 877
22. Subramanian B., Nakeff A., Tenney K., Crews P., Gunatilaka L., and Valeriote F. J. Exp. Ther. Oncol. 5 (2006) 195
23. Hormann A., Chaudhuri B., and Fretz H. Bioorg. Med. Chem. 9 (2001) 917
24. Aubry C.A., Jenkins P.R., Mahale S., Chaudhuri B., Marechal J.-D., and Sutcliffe M.J. Chem. Commun. 15 (2004) 1696
25. Aubry C.A., Wilson A.J., Jenkins P.R., Mahale S., Chaudhuri B., Maréchal J.-D., and Sutcliffe M.J. Org. Biomol. Chem. 4 (2006) 787
26. Garcia M.D., Wilson A.J., Emmerson D.P.G., and Jenkins P.R. Chem. Commun. 24 (2006) 2586
27. Garcia M.D., Wilson A.J., Emmerson D.P.G., Jenkins P.R., Mahale S., and Chaudhuri B. Org. Biomol. Chem. 424 (2006) 4484
28. Jenkins P.R., Wilson J., Emmerson D., García M.D., Smith M.R., Gray S.J., Britton R.G., Mahale S., and Chaudhuri B. Bioorg. Med. Chem. 16 (2008) 7728
29. Mahale S., Aubry C., Jenkins P.R., Maréchal J.-D., Sutcliffe M.J., and Chaudhuri B. Bioorg. Chem. 34 (2006) 287
30. Mahale S., Aubry C., Wilson A.J., Jenkins P.R., Maréchal J.-D., Sutcliffe M.J., and Chaudhuri B. Bioorg. Med. Chem. Lett. 16 (2006) 4272
31. Aubry C.A., Patel A., Mahale S., Chaudhuri B., Maréchal J.-D., Sutcliffe M.J., and Jenkins P.R. Tetrahedron Lett. 46 (2005) 1423
32. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. J. Mol. Biol. 267 (1997) 727
33. In our experience a Goldscore predicted >40 is indicative of a significant binding affinity; see for instance Refs. 16,17.
34. Shaw K.N.F., McMillan A., Gudmundson A.G., and Armstrong M.D. J. Org. Chem. 23 (1958) 1171
35. Gribble G.W., and Hoffman J.H. Synthesis (1977) 859
36. Gribble G.W., and Pelckman B.J. J. Org. Chem. 57 (1992) 3636
37. Sadanandan E.V., Pillai S.K., Lakshimikantham M.V., Billimoria A.D., Culpepper J.S., and Cava M.P.J. J. Org. Chem. 60 (1995) 1800
38. Cockroft S.L., Perkins J., Zonta C., Adams H., Spey S.E., Low C.M.R., Vinter J.G., Lawson K.R., Urch C.J., and Hunter C.A. Org. Biomol. Chem. 5 (2007) 1062
39. Phelps D., and Xiong Y. Methods Enzymol. 283 (1996) 194
40. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., and Moulinoux J.P. Eur. J. Biochem. 243 (1997) 527
41. Boris S., Richard L., and Robert L.S. J. Biol. Chem. 272 (1997) 33327
42. Grisar M., Petty M.A., Bolkenius F.N., Dow J., Wagner J., Wagner E.R., Haegele K.D., and Dejong W. J. Med. Chem. 34 (1991) 257
43. Biniecki S., and Modrzejewska W. Acta. Pol. Pharm. 38 (1981) 407